CCA
BMY icon

Cravens & Co Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Cravens & Co Advisors’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,611
Closed -$340K – 70
2026
Q1 		$340K Buy
5,611
+120
+2% +$7K 0.22% 54
2025
Q4 		$307K Sell
5,491
-23
-0.4% -$1.11K 0.2% 51
2025
Q3 		$249K Buy
5,514
+122
+2% +$5.7K 0.17% 53
2025
Q2 		$250K Buy
5,392
+88
+2% +$4.32K 0.19% 50
2025
Q1 		$323K Buy
5,304
+18
+0.3% +$1.05K 0.25% 45
2024
Q4 		$299K Buy
5,286
+8
+0.2% +$447 0.23% 52
2024
Q3 		$273K Sell
5,278
-565
-10% -$26.5K 0.21% 55
2024
Q2 		$243K Buy
+5,843
New +$261K 0.18% 64

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cravens & Co Advisors's BMY Position: Q2 2026 in Review

Cravens & Co Advisors sold out of Bristol-Myers Squibb (BMY) in Q2 2026, closing a stake of 5,611 shares — an estimated $340K sold.

Cravens & Co Advisors first reported a position in BMY in Q2 2024 and held it in 8 quarters. The position peaked at $340K in Q1 2026. 2,523 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Cravens & Co Advisors reported no remaining Bristol-Myers Squibb position as of Q2 2026 after selling out during the quarter.
  • Cravens & Co Advisors sold 5,611 Bristol-Myers Squibb shares in Q2 2026, an estimated $340K.
  • Cravens & Co Advisors first reported a position in Bristol-Myers Squibb in Q2 2024 and held it in 8 quarters.
  • Cravens & Co Advisors's Bristol-Myers Squibb position peaked at $340K in Q1 2026.
  • 2,523 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cravens & Co Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.